PEGylation Success Stories

FDA approved PEGylated drug

To date, eleven PEGylated proteins, antibody fragments, oligonucleotides, and small molecules have been approved by FDA are on the market, including PEGylated bovine adenosine deaminase: pegademase bovine (Adagen); and PEGylated l-asparaginase: pegaspargase (Oncaspar); PEGylated products of interferon-alpha (IFN-alpha): peginterferon-2b (PegIntron) and peginterferon-2a (Pegasys); PEGylated granulocyte colony stimulating factor (GCSF): pegfilgrastim (Neulasta); PEGylated growth hormone receptor […]

FDA Approves Constipation Drug PEGylated Naloxol

FDA has approved AstraZeneca’s Movantik for opioid-induced constipation in adults with chronic non-cancer pain. Movantik (naloxegol), an oral once-a-day treatment originally developed by Nektar Therapeutics, can decrease the constipating effects of opioids. The drug’s safety and effectiveness were established in two clinical trials. Naloxegol is PEGylated naloxol, which is a peripherally-selective opioid antagonist. It is […]

PEGylated Hyaluronic Acid Nanoparticle Drug Delivery

A research group from the Republic of Korea developed poly(ethylene glycol)-conjugated hyaluronic acid nanoparticles (PEG-HANPs) with high tumor targetability. Doxorubicin (DOX) was chosen as the model anticancer drug and was effectively encapsulated into the mineralized nanoparticles. “The most effective antitumor efficacy was observed for DOX-loaded PEG-HANPs. Overall, these results suggest that PEG-HANPs could be a […]

Fluorescent or Radioactive PEG-like Nanoprobes

Researchers from the Massachusetts General Hospital and Harvard Medical School developed novel “PEG-like Nanoprobes’’ with controllable pharmacokinetics and  tunable fluorescence. The “PEG-like Nanoprobes’’ nanoparticles feature a unique design where a single PEG polymer surrounds a short fluorochrome and radiometal bearing peptide, and endows the resulting nanoprobe with pharmacokinetic control (based on molecular weight of the […]

Designer Proteins Trigger Cell Death – a new cancer therapy?

Researchers from University of Washington and the Howard Hughes Medical Institute use an innovative computational design approach coupled with in-vitro-targeted evolution to produce a potent polypeptide inhibitor that triggers apoptosis of virus-infected cancer cells, suppresses tumor growth and extends survival in a xenograft model of EBV-positive human lymphoma. This represents an effort to generate biologically […]